Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Multiple Sclerosis

Free Subscription Articles published in J Neurol Neurosurg Psychiatry Retrieve available abstracts of 105 articles: HTML format

Single Articles

October 2025
1. FOONG YC, Merlo D, Gresle M, Buzzard K, et al
   Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
   J Neurol Neurosurg Psychiatry. 2025 Oct 29:jnnp-2025-336513.
   PubMed     Abstract available
   
   
   
2. MARIOTTINI A, Mazzeo AC, Simonetti E, Boncompagni R, et al
   Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study.
   J Neurol Neurosurg Psychiatry. 2025 Oct 20:jnnp-2025-336808.
   PubMed     Abstract available
   
   
   
3. VON KAPPELGAARD L, Framke E, Vassard D, Pinborg A, et al
   Relapse activity after assisted reproductive technology treatments in women with multiple sclerosis: a nationwide cohort study in Denmark.
   J Neurol Neurosurg Psychiatry. 2025 Oct 20:jnnp-2025-336080.
   PubMed     Abstract available
   
   
   
4. SAMARA A, Cohen JA
   Autologous haematopoietic stem cell transplantation in multiple sclerosis: where does it fit in the treatment algorithm?
   J Neurol Neurosurg Psychiatry. 2025 Oct 20:jnnp-2025-337492.
   PubMed    
   
   
   
5. PROSPERINI L, Tacchino A, Ruggieri S, Brichetto G, et al
   Home-based EXergames To impRovE cognitive function in MUltiple Sclerosis (EXTREMUS).
   J Neurol Neurosurg Psychiatry. 2025 Oct 1:jnnp-2025-336609.
   PubMed     Abstract available
   
   
   September 2025
6. HEDSTROM AK, Olsson T, Piehl F, Alfredsson L, et al
   Beneficial impact of physical activity on multiple sclerosis disability progression.
   J Neurol Neurosurg Psychiatry. 2025 Sep 23:jnnp-2025-336738.
   PubMed     Abstract available
   
   
   
7. MOLENAAR S, Scherbeijn S, Bruijstens A, Buijze MSJ, et al
   Strong association with remote EBV infection in children with MS as opposed to other acquired demyelinating disorders.
   J Neurol Neurosurg Psychiatry. 2025;96:975-980.
   PubMed     Abstract available
   
   
   
8. ZHAO Y, Fei L
   Smoking-attributable neurological health loss: age-specific burden and health disparities.
   J Neurol Neurosurg Psychiatry. 2025;96:937-946.
   PubMed     Abstract available
   
   
   
9. ELLENBERGER D, Flachenecker P, Haas J, Hellwig K, et al
   Paediatric-onset multiple sclerosis: demographics, symptoms and disease progression.
   J Neurol Neurosurg Psychiatry. 2025 Sep 8:jnnp-2025-336680.
   PubMed     Abstract available
   
   
   
10. MURARO PA, Kazmi M, De Matteis E, Brittain G, et al
    Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK.
    J Neurol Neurosurg Psychiatry. 2025 Sep 5:jnnp-2025-336755.
    PubMed     Abstract available
    
    
    
11. GAVOILLE A, Nourredine M, Rollot F, Casey R, et al
    Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Sep 4:jnnp-2025-336762.
    PubMed     Abstract available
    
    
    
12. CALVI A, Vivo Pascual F, Solana E, Lopez-Soley E, et al
    Diffusivity anisotropy signature of the slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Sep 1:jnnp-2025-335884.
    PubMed     Abstract available
    
    
    July 2025
13. ROBERTS JI, Sharmin S, Horakova D, Kubala Havrdova E, et al
    Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
    J Neurol Neurosurg Psychiatry. 2025 Jul 28:jnnp-2025-336343.
    PubMed     Abstract available
    
    
    
14. SYC-MAZUREK SB, Cacciaguerra L, Tajfirouz DA, Redenbaugh V, et al
    MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Jul 20:jnnp-2025-336684.
    PubMed     Abstract available
    
    
    
15. BOCCIA VD, Leveraro E, Cipriano E, Lapucci C, et al
    Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesions.
    J Neurol Neurosurg Psychiatry. 2025;96:807-813.
    PubMed     Abstract available
    
    
    
16. TAN H, Deng X, ZhangBao J, Zhou L, et al
    KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort.
    J Neurol Neurosurg Psychiatry. 2025 Jul 11:jnnp-2025-335953.
    PubMed     Abstract available
    
    
    June 2025
17. BAKER D, Alfredsson L, Hedstrom AK, Schmierer K, et al
    Mechanistic biology linking traumatic brain injury to multiple sclerosis susceptibility.
    J Neurol Neurosurg Psychiatry. 2025 Jun 27:jnnp-2024-335304.
    PubMed     Abstract available
    
    
    
18. ZANGHI A, Copetti M, Avolio C, Paolicelli D, et al
    Multiple sclerosis from onset to secondary progression: a 30-year Italian register study.
    J Neurol Neurosurg Psychiatry. 2025 Jun 15:jnnp-2025-335958.
    PubMed     Abstract available
    
    
    
19. ABDELHAK A, Bachhuber F, Ning K, Benkert P, et al
    Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.
    J Neurol Neurosurg Psychiatry. 2025 Jun 12:jnnp-2025-335831.
    PubMed     Abstract available
    
    
    
20. YAMOUT B, Alroughani R, Mohamed SFA, Al-Mahdawi AM, et al
    Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study.
    J Neurol Neurosurg Psychiatry. 2025 Jun 1:jnnp-2024-335704.
    PubMed     Abstract available
    
    
    May 2025
21. SALTER A, Lancia S, Kowalec K, Fitzgerald K, et al
    Comorbidities, safety and persistence in phase III clinical trials in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 May 24:jnnp-2024-335710.
    PubMed     Abstract available
    
    
    
22. AHOLA V, Saraste M, Nylund M, Matilainen M, et al
    Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 May 16:jnnp-2025-336063.
    PubMed     Abstract available
    
    
    
23. LORSCHEIDER J, Signori A, Subramaniam S, Benkert P, et al
    Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
    J Neurol Neurosurg Psychiatry. 2025;96:606-615.
    PubMed     Abstract available
    
    
    April 2025
24. RUSKA B, Adamec I, Crnosija L, Gabelic T, et al
    Evolution of autonomic nervous system abnormalities in multiple sclerosis: a 6-year follow-up.
    J Neurol Neurosurg Psychiatry. 2025 Apr 24:jnnp-2024-335376.
    PubMed     Abstract available
    
    
    
25. ZICCARDI S, Guandalini M, Crescenzo F, Martinelli L, et al
    Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course.
    J Neurol Neurosurg Psychiatry. 2025 Apr 23:jnnp-2025-335925.
    PubMed     Abstract available
    
    
    
26. YAM C, Brownlee WJ, Prados Carrasco F, Toosy A, et al
    Investigating colour vision and its structural correlates 15 years following a first demyelinating event.
    J Neurol Neurosurg Psychiatry. 2025;96:435-442.
    PubMed     Abstract available
    
    
    March 2025
27. SHIPLEY J, Beadnall H, Butzkueven H, van der Walt A, et al
    Impact of pregnancy on the maternal brain in health and multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335319.
    PubMed     Abstract available
    
    
    
28. MANOUCHEHRINIA A, Zhu F, Hillert J, McKay K, et al
    Prodromal phase of multiple sclerosis: evidence from sickness absence patterns before disease onset - a matched cohort study.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335279.
    PubMed     Abstract available
    
    
    
29. GELISSEN LMY, Toorop AA, Schipper PM, Hoitsma E, et al
    Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335761.
    PubMed     Abstract available
    
    
    
30. GIORDANO A, Giliberti A, Clarelli F, Misra K, et al
    Sex hormone-related factors and the risk of PIRA in women with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 13:jnnp-2024-335547.
    PubMed     Abstract available
    
    
    
31. DZAU W, Roos I, Kalincik T
    Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335495.
    PubMed     Abstract available
    
    
    
32. WINTER P, Axhausen F, Wolff S, Willison AG, et al
    Association of body mass index and clinical response in patients receiving ofatumumab for treatment of multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335673.
    PubMed     Abstract available
    
    
    
33. NOUI Y, Zjukovskaja C, Silfverberg T, Ljungman P, et al
    Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Mar 6:jnnp-2024-335512.
    PubMed     Abstract available
    
    
    February 2025
34. JOHANSSON E, Guo J, Wu J, Olsson T, et al
    Impact of fish consumption on disability progression in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Feb 25:jnnp-2024-335200.
    PubMed     Abstract available
    
    
    
35. LAUERER M, Wiltgen T, Bruckner C, Engl C, et al
    Predictors of early disability accumulation in newly diagnosed multiple sclerosis: clinical, imaging and cerebrospinal fluid measures.
    J Neurol Neurosurg Psychiatry. 2025 Feb 17:jnnp-2024-335037.
    PubMed     Abstract available
    
    
    
36. GUO J, Olsson T, Hillert J, Alfredsson L, et al
    Lifestyle factors associated with benign multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2025 Feb 13:jnnp-2024-335464.
    PubMed     Abstract available
    
    
    January 2025
37. GOMBOLAY G, Johnson L, King R, Hebert M, et al
    Worldwide epidemiology of paediatric multiple sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition.
    J Neurol Neurosurg Psychiatry. 2025 Jan 23:jnnp-2024-335175.
    PubMed     Abstract available
    
    
    December 2024
38. DE ANGELIS F, Cameron JR, Eshaghi A, Parker R, et al
    Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
    J Neurol Neurosurg Psychiatry. 2024 Dec 18:jnnp-2024-334801.
    PubMed     Abstract available
    
    
    
39. DE MOL CL, Lamballais S, Muetzel R, Duijts L, et al
    Environmental multiple sclerosis (MS) risk factors, genetic MS risk, and brain development in a general paediatric population.
    J Neurol Neurosurg Psychiatry. 2024 Dec 10:jnnp-2024-335053.
    PubMed     Abstract available
    
    
    
40. JEANTIN L, Bensa-Koscher C, Deschamps R, Gout O, et al
    Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning.
    J Neurol Neurosurg Psychiatry. 2024 Dec 4:jnnp-2024-334629.
    PubMed    
    
    
    October 2024
41. RUBIN M, Preziosa P, Margoni M, Meani A, et al
    Dynamics of choroid plexus volume is associated with the presence and development of fatigue in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Oct 10:jnnp-2024-334913.
    PubMed     Abstract available
    
    
    September 2024
42. SCHOEPS VA, Bhargava P, Virupakshaiah A, Ladakis DC, et al
    Distinct plasma lipids predict axonal injury and multiple sclerosis activity.
    J Neurol Neurosurg Psychiatry. 2024 Sep 12:jnnp-2024-333652.
    PubMed     Abstract available
    
    
    
43. ZARGHAMI A, Hussain MA, van der Mei I, Simpson-Yap S, et al
    Long-term disability trajectories in multiple sclerosis: a group-based trajectory analysis of the AusLong cohort.
    J Neurol Neurosurg Psychiatry. 2024 Sep 4:jnnp-2024-333632.
    PubMed     Abstract available
    
    
    August 2024
44. GHEZZI L, Tosti V, Shi L, Cantoni C, et al
    Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Aug 13:jnnp-2024-333465.
    PubMed     Abstract available
    
    
    July 2024
45. ANANTHAVARATHAN P, Sahi N, Chung K, Haider L, et al
    The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jul 22:jnnp-2024-333917.
    PubMed     Abstract available
    
    
    
46. MIN YG, Moon Y, Kwon YN, Lee BJ, et al
    Prognostic factors of first-onset optic neuritis based on diagnostic criteria and antibody status: a multicentre analysis of 427 eyes.
    J Neurol Neurosurg Psychiatry. 2024;95:753-760.
    PubMed     Abstract available
    
    
    
47. GIORDANO A, Clarelli F, Pignolet B, Mascia E, et al
    Vitamin D affects the risk of disease activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jul 14:jnnp-2024-334062.
    PubMed     Abstract available
    
    
    
48. GOODIN DS
    Pathogenesis of multiple sclerosis: genetic, environmental and random mechanisms.
    J Neurol Neurosurg Psychiatry. 2024 Jul 2:jnnp-2023-333296.
    PubMed     Abstract available
    
    
    June 2024
49. SHI L, Ghezzi L, Fenoglio C, Pietroboni AM, et al
    CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Jun 6:jnnp-2024-333774.
    PubMed     Abstract available
    
    
    
50. DAS J, Mallawaarachchi G, Grimshaw J, Jackson T, et al
    Ethnicity and deprivation negatively impact the access to disease-modifying therapy for relapsing-remitting multiple sclerosis: a retrospective, single-centre study.
    J Neurol Neurosurg Psychiatry. 2024 Jun 5:jnnp-2024-333338.
    PubMed     Abstract available
    
    
    May 2024
51. NICHOLAS R, Tallantyre EC, Witts J, Marrie RA, et al
    Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales.
    J Neurol Neurosurg Psychiatry. 2024 May 23:jnnp-2024-333532.
    PubMed     Abstract available
    
    
    
52. ROCCA MA, Valsasina P, Romano F, Tedone N, et al
    Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial.
    J Neurol Neurosurg Psychiatry. 2024 May 16:jnnp-2024-333460.
    PubMed     Abstract available
    
    
    
53. ENGLUND S, Frisell T, Qu Y, Gandhi K, et al
    Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.
    J Neurol Neurosurg Psychiatry. 2024 May 14:jnnp-2024-333595.
    PubMed     Abstract available
    
    
    
54. VIRTANEN S, Piehl F, Frisell T
    Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study.
    J Neurol Neurosurg Psychiatry. 2024 May 14:jnnp-2023-333206.
    PubMed     Abstract available
    
    
    
55. THIEL S, Litvin N, Haben S, Gold R, et al
    Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy.
    J Neurol Neurosurg Psychiatry. 2024;95:561-570.
    PubMed     Abstract available
    
    
    
56. MAAROUF A, Stellmann JP, Rico A, Boutiere C, et al
    Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 May 6:jnnp-2024-333597.
    PubMed     Abstract available
    
    
    April 2024
57. ABDEL-MANNAN O, Champsas D, Tur C, Lee V, et al
    Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course.
    J Neurol Neurosurg Psychiatry. 2024;95:426-433.
    PubMed     Abstract available
    
    
    
58. MAHLER MR, Magyari M, Pontieri L, Elberling F, et al
    Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study.
    J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333265.
    PubMed     Abstract available
    
    
    
59. DEKEYSER C, Hautekeete M, Cambron M, Van Pesch V, et al
    Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
    J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333307.
    PubMed     Abstract available
    
    
    March 2024
60. VERSTEGEN NJM, Hagen RR, Kreher C, Kuijper LH, et al
    T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
    J Neurol Neurosurg Psychiatry. 2024 Mar 28:jnnp-2023-332224.
    PubMed     Abstract available
    
    
    
61. KALINCIK T, Sharmin S, Roos I, Massey J, et al
    Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2024 Mar 27:jnnp-2023-332790.
    PubMed     Abstract available
    
    
    
62. JONS D, Grut V, Bergstrom T, Zetterberg H, et al
    Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.
    J Neurol Neurosurg Psychiatry. 2024;95:325-332.
    PubMed     Abstract available
    
    
    
63. FOONG YC, Merlo D, Gresle M, Buzzard K, et al
    Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883.
    PubMed     Abstract available
    
    
    
64. JING J, Zhang Z, Su L, Gao C, et al
    Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332566.
    PubMed     Abstract available
    
    
    February 2024
65. POZZILLI V, Haggiag S, Di Filippo M, Capone F, et al
    Incidence and determinants of seizures in multiple sclerosis: a meta-analysis of randomised clinical trials.
    J Neurol Neurosurg Psychiatry. 2024 Feb 21:jnnp-2023-332996.
    PubMed     Abstract available
    
    
    
66. IOANNIDIS JP
    Therapeutic interventions increasing seizure risk in multiple sclerosis: resolving discordant meta-analyses.
    J Neurol Neurosurg Psychiatry. 2024 Feb 21:jnnp-2024-333329.
    PubMed    
    
    
    January 2024
67. SIGNORI A, Ponzano M, Kalincik T, Ozakbas S, et al
    Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
    J Neurol Neurosurg Psychiatry. 2024 Jan 19:jnnp-2023-332603.
    PubMed     Abstract available
    
    
    
68. JOHANSSON E, Alfredsson L, Strid P, Kockum I, et al
    Head trauma results in manyfold increased risk of multiple sclerosis in genetically susceptible individuals.
    J Neurol Neurosurg Psychiatry. 2024 Jan 11:jnnp-2023-332643.
    PubMed     Abstract available
    
    
    December 2023
69. ELSBERND P, Cacciaguerra L, Krecke KN, Chen JJ, et al
    Cerebral enhancement in MOG antibody-associated disease.
    J Neurol Neurosurg Psychiatry. 2023;95:14-18.
    PubMed     Abstract available
    
    
    
70. ZIVADINOV R, Pei J, Clayton D, Goldman DE, et al
    Evolution of atrophied T2 lesion volume in primary-progressive multiple sclerosis: results from the phase 3 ORATORIO study.
    J Neurol Neurosurg Psychiatry. 2023 Dec 6:jnnp-2023-332573.
    PubMed     Abstract available
    
    
    November 2023
71. ALBA-ARBALAT S, Solana E, Lopez-Soley E, Camos-Carreras A, et al
    Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Nov 21:jnnp-2023-332332.
    PubMed     Abstract available
    
    
    
72. KOCH M
    Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332758.
    PubMed    
    
    
    
73. TOOROP AA, van Lierop ZY, Gelissen LM, Hoitsma E, et al
    Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    J Neurol Neurosurg Psychiatry. 2023 Nov 14:jnnp-2023-332119.
    PubMed     Abstract available
    
    
    
74. FISSOLO N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, et al
    Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Nov 8:jnnp-2023-332251.
    PubMed     Abstract available
    
    
    
75. PALMER AJ, Zhao T, Taylor BV, van der Mei I, et al
    Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting.
    J Neurol Neurosurg Psychiatry. 2023 Nov 2:jnnp-2023-332161.
    PubMed     Abstract available
    
    
    October 2023
76. CAMPBELL JA, van der Mei I, Taylor BV, Palmer AJ, et al
    Using qualitative free-text data to investigate the lived experience of the COVID-19 pandemic for a large cohort of Australians with different multiple sclerosis related disability levels.
    J Neurol Neurosurg Psychiatry. 2023 Oct 26:jnnp-2022-330755.
    PubMed     Abstract available
    
    
    
77. MONTINI F, Nozzolillo A, Tedone N, Mistri D, et al
    COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study.
    J Neurol Neurosurg Psychiatry. 2023 Oct 19:jnnp-2023-332073.
    PubMed     Abstract available
    
    
    
78. MAIWORM M, Hamid C, Wagner M, Noth U, et al
    Multiparametric quantitative MRI reveals progressive cortical damage over time in clinically stable relapsing-remitting MS.
    J Neurol Neurosurg Psychiatry. 2023;94:786-791.
    PubMed     Abstract available
    
    
    September 2023
79. RUGGIERI S, Prosperini L, Al-Araji S, Annovazzi PO, et al
    Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.
    J Neurol Neurosurg Psychiatry. 2023 Sep 29:jnnp-2023-331920.
    PubMed     Abstract available
    
    
    
80. SILFVERBERG T, Zjukovskaja C, Ljungman P, Nahimi A, et al
    Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
    J Neurol Neurosurg Psychiatry. 2023 Sep 25:jnnp-2023-331864.
    PubMed     Abstract available
    
    
    
81. YUSUF FLA, Asaf A, Marrie RA, Li P, et al
    Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada's population.
    J Neurol Neurosurg Psychiatry. 2023 Sep 21:jnnp-2023-331991.
    PubMed     Abstract available
    
    
    August 2023
82. GAY MC, Cassedanne F, Barbot F, Vaugier I, et al
    Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care.
    J Neurol Neurosurg Psychiatry. 2023 Aug 30:jnnp-2023-331537.
    PubMed     Abstract available
    
    
    
83. LONGINETTI E, Englund S, Burman J, Fink K, et al
    Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.
    J Neurol Neurosurg Psychiatry. 2023 Aug 9:jnnp-2023-331784.
    PubMed     Abstract available
    
    
    
84. MASCARENAS-GARCIA M, Rivero-de-Aguilar A, Perez-Rios M, Ruano-Ravina A, et al
    Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials.
    J Neurol Neurosurg Psychiatry. 2023 Aug 4:jnnp-2023-331733.
    PubMed     Abstract available
    
    
    
85. HABEN S, Ciplea AI, Tokic M, Timmesfeld N, et al
    Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Aug 3:jnnp-2023-331525.
    PubMed     Abstract available
    
    
    July 2023
86. LAUERER M, McGinnis J, Bussas M, El Husseini M, et al
    Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 26:jnnp-2023-331799.
    PubMed     Abstract available
    
    
    
87. KAPALI A, Daltveit AK, Myhr KM, Bjornevik K, et al
    Childbirth delivery mode and the risk of multiple sclerosis: a prospective population-based study.
    J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331241.
    PubMed     Abstract available
    
    
    
88. JEANTIN L, Abdi B, Soulie C, Sterlin D, et al
    Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
    J Neurol Neurosurg Psychiatry. 2023 Jul 21:jnnp-2023-331770.
    PubMed     Abstract available
    
    
    
89. MOROZUMI T, Preziosa P, Meani A, Albergoni M, et al
    Influence of cardiorespiratory fitness and MRI measures of neuroinflammation on hippocampal volume in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 19:jnnp-2023-331482.
    PubMed     Abstract available
    
    
    
90. COLATO E, Prados F, Stutters J, Bianchi A, et al
    Networks of microstructural damage predict disability in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 19:jnnp-2022-330203.
    PubMed     Abstract available
    
    
    
91. ROSENKRANZ SC, Gutmann L, Has Silemek AC, Dorr M, et al
    Visual function resists early neurodegeneration in the visual system in primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Jul 11:jnnp-2023-331183.
    PubMed     Abstract available
    
    
    
92. DZAU W, Sharmin S, Patti F, Izquierdo G, et al
    Risk of secondary progressive multiple sclerosis after early worsening of disability.
    J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331748.
    PubMed     Abstract available
    
    
    
93. DIOUF I, Malpas CB, Sharmin S, Roos I, et al
    Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
    J Neurol Neurosurg Psychiatry. 2023 Jul 6:jnnp-2023-331499.
    PubMed     Abstract available
    
    
    June 2023
94. MARTINEZ-HERAS E, Solana E, Vivo F, Lopez-Soley E, et al
    Diffusion-based structural connectivity patterns of multiple sclerosis phenotypes.
    J Neurol Neurosurg Psychiatry. 2023 Jun 15:jnnp-2023-331531.
    PubMed     Abstract available
    
    
    
95. HOUZEN H, Kano T, Kondo K, Takahashi T, et al
    Prevalence, incidence and clinical features of neuromyelitis optica spectrum disorders in northern Japan.
    J Neurol Neurosurg Psychiatry. 2023;94:494-495.
    PubMed    
    
    
    May 2023
96. STRIJBIS EM, Coerver E, Mostert J, van Kempen ZLE, et al
    Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 May 12:jnnp-2022-330887.
    PubMed     Abstract available
    
    
    
97. SARASTE M, Matilainen M, Vuorimaa A, Laaksonen S, et al
    Association of serum neurofilament light with microglial activation in multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 May 2:jnnp-2023-331051.
    PubMed     Abstract available
    
    
    April 2023
98. NOVAK F, Bajwa HM, Coia JE, Nilsson AC, et al
    Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
    J Neurol Neurosurg Psychiatry. 2023 Apr 25:jnnp-2022-330757.
    PubMed     Abstract available
    
    
    
99. LEPPERT D, Watanabe M, Schaedelin S, Piehl F, et al
    Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Apr 19:jnnp-2022-330796.
    PubMed     Abstract available
    
    
    
100. HARDING-FORRESTER S, Roos I, Nguyen AL, Malpas CB, et al
     Disability accrual in primary and secondary progressive multiple sclerosis.
     J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330726.
     PubMed     Abstract available
     
     
     
101. MOCCIA M, Affinito G, Fumo MG, Giordana R, et al
     Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020.
     J Neurol Neurosurg Psychiatry. 2023 Apr 17:jnnp-2022-330883.
     PubMed     Abstract available
     
     
     March 2023
102. WU J, Olsson T, Hillert J, Alfredsson L, et al
     Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression.
     J Neurol Neurosurg Psychiatry. 2023 Mar 31:jnnp-2022-330848.
     PubMed     Abstract available
     
     
     
103. MARGONI M, Preziosa P, Storelli L, Gueye M, et al
     Paramagnetic rim and core sign lesions in paediatric multiple sclerosis patients.
     J Neurol Neurosurg Psychiatry. 2023 Mar 29:jnnp-2022-331027.
     PubMed    
     
     
     
104. RIVERO-DE-AGUILAR A, Perez-Rios M, Ruano-Ravina A, Candal-Pedreira C, et al
     Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov.
     J Neurol Neurosurg Psychiatry. 2023 Mar 28:jnnp-2023-331132.
     PubMed     Abstract available
     
     
     
105. LEADBETTER R, MacAskill M, Myall DJ, Taylor BV, et al
     Multiple sclerosis mortality in New Zealand: a nationwide prospective study.
     J Neurol Neurosurg Psychiatry. 2023 Mar 7:jnnp-2022-330582.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.